Literature DB >> 33399966

Cortical progression patterns in individual ALS patients across multiple timepoints: a mosaic-based approach for clinical use.

Marlene Tahedl1,2,3, Rangariroyashe H Chipika1, Jasmin Lope1, Stacey Li Hi Shing1, Orla Hardiman1, Peter Bede4.   

Abstract

INTRODUCTION: The majority of imaging studies in ALS infer group-level imaging signatures from group comparisons, as opposed to estimating disease burden in individual patients. In a condition with considerable clinical heterogeneity, the characterisation of individual patterns of pathology is hugely relevant. In this study, we evaluate a strategy to track progressive cortical involvement in single patients by using subject-specific reference cohorts.
METHODS: We have interrogated a multi-timepoint longitudinal dataset of 61 ALS patients to demonstrate the utility of estimating cortical disease burden and the expansion of cerebral atrophy over time. We contrast our strategy to the gold-standard approach to gauge the advantages and drawbacks of our method. We modelled the evolution of cortical integrity in a conditional growth model, in which we accounted for age, gender, disability, symptom duration, education and handedness. We hypothesised that the variance associated with demographic variables will be successfully eliminated in our approach.
RESULTS: In our model, the only covariate which modulated the expansion of atrophy was motor disability as measured by the ALSFRS-r (t(153) = - 2.533, p = 0.0123). Using the standard approach, age also significantly influenced progression of CT change (t(153) = - 2.151, p = 0.033) demonstrating the validity and potential clinical utility of our approach.
CONCLUSION: Our strategy of estimating the extent of cortical atrophy in individual patients with ALS successfully corrects for demographic factors and captures relevant cortical changes associated with clinical disability. Our approach provides a framework to interpret single T1-weighted images in ALS and offers an opportunity to track cortical propagation patterns both at individual subject level and at cohort level.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; Biomarkers; Cortical thickness; Longitudinal study; MRI; Neuroimaging

Mesh:

Year:  2021        PMID: 33399966     DOI: 10.1007/s00415-020-10368-7

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  74 in total

1.  Presymptomatic spinal cord pathology in c9orf72 mutation carriers: A longitudinal neuroimaging study.

Authors:  Giorgia Querin; Peter Bede; Mohamed Mounir El Mendili; Menghan Li; Mélanie Pélégrini-Issac; Daisy Rinaldi; Martin Catala; Dario Saracino; François Salachas; Agnes Camuzat; Véronique Marchand-Pauvert; Julien Cohen-Adad; Olivier Colliot; Isabelle Le Ber; Pierre-François Pradat
Journal:  Ann Neurol       Date:  2019-06-27       Impact factor: 10.422

Review 2.  Presymptomatic and longitudinal neuroimaging in neurodegeneration--from snapshots to motion picture: a systematic review.

Authors:  Christina Schuster; Marwa Elamin; Orla Hardiman; Peter Bede
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-01-28       Impact factor: 10.154

Review 3.  Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved?

Authors:  Hiroshi Mitsumoto; Benjamin R Brooks; Vincenzo Silani
Journal:  Lancet Neurol       Date:  2014-11       Impact factor: 44.182

4.  Development of an Automated MRI-Based Diagnostic Protocol for Amyotrophic Lateral Sclerosis Using Disease-Specific Pathognomonic Features: A Quantitative Disease-State Classification Study.

Authors:  Christina Schuster; Orla Hardiman; Peter Bede
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240

5.  A pharmaco-metabolomics approach in a clinical trial of ALS: Identification of predictive markers of progression.

Authors:  Hélène Blasco; Franck Patin; Amandine Descat; Guillaume Garçon; Philippe Corcia; Patrick Gelé; Timothée Lenglet; Peter Bede; Vincent Meininger; David Devos; Jean François Gossens; Pierre-François Pradat
Journal:  PLoS One       Date:  2018-06-05       Impact factor: 3.240

Review 6.  Biomarkers for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Associated With Hexanucleotide Expansion Mutations in C9orf72.

Authors:  Mary Kay Floeter; Tania F Gendron
Journal:  Front Neurol       Date:  2018-12-05       Impact factor: 4.003

Review 7.  Tracking a Fast-Moving Disease: Longitudinal Markers, Monitoring, and Clinical Trial Endpoints in ALS.

Authors:  Rangariroyashe Hannah Chipika; Eoin Finegan; Stacey Li Hi Shing; Orla Hardiman; Peter Bede
Journal:  Front Neurol       Date:  2019-03-19       Impact factor: 4.003

Review 8.  Imaging Cerebral Activity in Amyotrophic Lateral Sclerosis.

Authors:  Malcolm Proudfoot; Peter Bede; Martin R Turner
Journal:  Front Neurol       Date:  2019-01-08       Impact factor: 4.003

9.  A ferroptosis-based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis.

Authors:  David Devos; Caroline Moreau; Maeva Kyheng; Guillaume Garçon; Anne Sophie Rolland; Hélène Blasco; Patrick Gelé; T Timothée Lenglet; C Veyrat-Durebex; Philippe Corcia; Mary Dutheil; Peter Bede; Andreas Jeromin; Patrick Oeckl; Markus Otto; Vincent Meininger; Véronique Danel-Brunaud; Jean-Christophe Devedjian; James A Duce; Pierre François Pradat
Journal:  Sci Rep       Date:  2019-02-27       Impact factor: 4.379

10.  Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.

Authors:  Timothy Miller; Merit Cudkowicz; Pamela J Shaw; Peter M Andersen; Nazem Atassi; Robert C Bucelli; Angela Genge; Jonathan Glass; Shafeeq Ladha; Albert L Ludolph; Nicholas J Maragakis; Christopher J McDermott; Alan Pestronk; John Ravits; François Salachas; Randall Trudell; Philip Van Damme; Lorne Zinman; C Frank Bennett; Roger Lane; Alfred Sandrock; Heiko Runz; Danielle Graham; Hani Houshyar; Alexander McCampbell; Ivan Nestorov; Ih Chang; Manjit McNeill; Laura Fanning; Stephanie Fradette; Toby A Ferguson
Journal:  N Engl J Med       Date:  2020-07-09       Impact factor: 91.245

View more
  5 in total

1.  Pathological neural networks and artificial neural networks in ALS: diagnostic classification based on pathognomonic neuroimaging features.

Authors:  Peter Bede; Aizuri Murad; Orla Hardiman
Journal:  J Neurol       Date:  2021-09-28       Impact factor: 6.682

2.  Infratentorial pathology in frontotemporal dementia: cerebellar grey and white matter alterations in FTD phenotypes.

Authors:  Mary Clare McKenna; Rangariroyashe H Chipika; Stacey Li Hi Shing; Foteini Christidi; Jasmin Lope; Mark A Doherty; Jennifer C Hengeveld; Alice Vajda; Russell L McLaughlin; Orla Hardiman; Siobhan Hutchinson; Peter Bede
Journal:  J Neurol       Date:  2021-05-13       Impact factor: 6.682

3.  White matter microstructure alterations in frontotemporal dementia: Phenotype-associated signatures and single-subject interpretation.

Authors:  Mary Clare McKenna; Marlene Tahedl; Aizuri Murad; Jasmin Lope; Orla Hardiman; Siobhan Hutchinson; Peter Bede
Journal:  Brain Behav       Date:  2022-01-24       Impact factor: 2.708

4.  Mapping cortical disease-burden at individual-level in frontotemporal dementia: implications for clinical care and pharmacological trials.

Authors:  Mary Clare McKenna; Marlene Tahedl; Jasmin Lope; Rangariroyashe H Chipika; Stacey Li Hi Shing; Mark A Doherty; Jennifer C Hengeveld; Alice Vajda; Russell L McLaughlin; Orla Hardiman; Siobhan Hutchinson; Peter Bede
Journal:  Brain Imaging Behav       Date:  2021-12-09       Impact factor: 3.224

5.  How to Arrange Follow-Up Time-Intervals for Longitudinal Brain MRI Studies in Neurodegenerative Diseases.

Authors:  Hans-Peter Müller; Anna Behler; G Bernhard Landwehrmeyer; Hans-Jürgen Huppertz; Jan Kassubek
Journal:  Front Neurosci       Date:  2021-07-15       Impact factor: 4.677

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.